3Treon SP,Shima Y,Raje N,et al.Interferon-g induces CD20 expression on multiple myeloma cells via induction of Pu.1 and augments rituximab binding to myeloma cells.Blood,2000,94 (Suppl 1):119a-123a.
4Einfeld DA,Brown JP,Valentine MA,et al.Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.Embo Jm,1988,7:711-717.
5Maloney DG,Liles TM,Czerwinski DK,et al.Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8 in patients with recurrent B-cell lymphoma.Blood,1994,84:2457-2466.
6Reff ME,Carner K,Chambers KS,et al.Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.Blood,1994,83:435-445.
7Maloney DG,Smith B,Appelbaum FR.The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines.Blood,1996,88 (Suppl1):637-644.
8Gong Q,Ou Q,Ye S,et al.Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy.J Immunol,2005,174:817-826.
9Nimmerjahn F,Ravetch JV.Divergent immunoglobulin g subclass activity through selective Fc receptor binding.Science,2005,310:1510-1512.
10Cartron G,Dacheux L,Salles G,et al.Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.Blood,2002,99:754-758.
